Atai Life Sciences N.V.
ATAI
$4.83
$0.091.90%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -53.76% | 31,200.00% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -53.76% | 31,200.00% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | 107.75% | -185,560.00% | |||
| SG&A Expenses | 49.19% | -12.72% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 24.81% | -29.02% | |||
| Operating Income | -31.15% | 34.34% | |||
| Income Before Tax | -5.10% | 33.67% | |||
| Income Tax Expenses | -49.22% | 117.83% | |||
| Earnings from Continuing Operations | -4.84% | 32.13% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -50.00% | 3.03% | |||
| Net Income | -4.91% | 32.16% | |||
| EBIT | -31.15% | 34.34% | |||
| EBITDA | -31.45% | 34.57% | |||
| EPS Basic | 5.87% | 38.16% | |||
| Normalized Basic EPS | 16.84% | 6.80% | |||
| EPS Diluted | 5.87% | 38.16% | |||
| Normalized Diluted EPS | 16.84% | 6.80% | |||
| Average Basic Shares Outstanding | 11.51% | 9.68% | |||
| Average Diluted Shares Outstanding | 11.51% | 9.68% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||